Our findings align with prior research on different molecular alterations suggest that TERTp/BRAF V600E and TERTp/RAS molecular alterations may behave differently and should be studied separately in larger cohorts with greater statistical power to better understand their distinct impacts on thyroid cancer progression. The gene discussed is BRAF; the disease is thyroid gland carcinoma.